pancreatic cancer

European Union flag

Pharma

Lilly, RevMed win key recommendations from European regulators

Across the pond, European regulators handed down a pair of pivotal approval recommendations for Eli Lilly and Revolution Medicines this week.

Fraiser Kansteiner Oct 16, 2026 11:30am

paper paperclips

FDA’s Rasonque review documents pressure RevMed

Oct 9, 2026 11:25am

launch

As RevMed preps for ‘historic’ cancer launch, questions linger

Aug 27, 2026 11:27am

Revolution Medicines booth at ASCO 2026

FDA greenlights RevMed’s pancreatic cancer gamechanger

Aug 26, 2026 11:30am

yellow light street light traffic pause slow delay

Verastem mulls options on approved asset in pancreatic cancer

Jun 17, 2026 3:00pm

Revolution Medicines booth at ASCO 2026

Fierce Biotech

ASCO: RevMed confident in RAS leadership as rivals square up

May 31, 2026 8:00am